Author

Marta Cossa

Observed name: M. Cossa

Institution: Manhiça Health Research Centre

Observed institution: Manhiça Health Research Centre

ORCID: 0009-0006-4041-1500

Observed ORCID: 0009-0006-4041-1500

OpenAlex ID: A5075109276

Performance of Xpert MTB/RIF Ultra for tuberculosis diagnosis in the context of passive and active case finding

2021 · Belén Saavedra, Edson Mambuque, et al. · European Respiratory Journal · 26

Decentralized TB diagnostic testing with Truenat MTB Plus and MTB-RIF Dx vs. hub-and-spoke GeneXpert MTB/RIF Ultra in Mozambique and Tanzania: a cost and cost-effectiveness analysis

2025 · Akash Malhotra, Délio Elísio, et al. · PLOS Global Public Health · 15

Reflex Xpert MTB/XDR Testing of Residual Rifampicin-Resistant Specimens: A Clinical Laboratory-Based Diagnostic Accuracy and Feasibility Study in South Africa

2024 · C M Centner, R Munir, et al. · Open Forum Infectious Diseases · 12

Implementation of WHO guidelines on urine lateral flow LAM testing in high TB/HIV burden African countries

2023 · Kaila Aguiar Soares, Joanna Ehrlich, et al. · European Respiratory Journal · 12

Epidemiology: the current burden of tuberculosis and its determinants

2023 · Rita Verstraeten, Marta Cossa, et al. · European Respiratory Society eBooks · 11

Expanding Xpert MTB/RIF Ultra® and LF-LAM testing for diagnosis of tuberculosis among HIV-positive adults admitted to hospitals in Tanzania and Mozambique: a randomized controlled trial (the EXULTANT trial)

2024 · Chacha Mangu, Marta Cossa, et al. · BMC Infectious Diseases · 9

Study protocol: a pragmatic, cluster-randomized controlled trial to evaluate the effect of implementation of the Truenat platform/MTB assays at primary health care clinics in Mozambique and Tanzania (TB-CAPT CORE)

2024 · V. N. Leukes, J. Hella, et al. · BMC Infectious Diseases · 6

Expanding Xpert MTB/RIF Ultra and lateral flow urine lipoarabinomannan testing for diagnosis of tuberculosis among adults living with HIV admitted to hospitals in Tanzania and Mozambique (EXULTANT): a randomised controlled trial

2026 · Marta Cossa, Robert Ndege, et al. · The Lancet Infectious Diseases · 4

Implementing the Molbio Truenat platform and tuberculosis assays versus standard of care at primary care clinics for the detection and treatment of tuberculosis in Mozambique and Tanzania (TB-CAPT CORE): a cluster-randomised trial

2025 · Celso Khosa, Marta Cossa, et al. · The Lancet Primary Care · 4

User perspectives on the Molbio Truenat platform and tuberculosis assays for decentralised testing in Mozambique and Tanzania

2026 · Maria del Mar Castro, Celso Khosa, et al. · BMJ Global Health · 1

The urgent need to improve on low implementation rates for TB preventive treatment for people living with HIV

2024 · M. Cossa, D. Nguenha, et al. · The International Journal of Tuberculosis and Lung Disease

The Effect of Implementing the Molbio Truenat Platform and Tuberculosis Assays at Primary Health Care Clinics in Mozambique and Tanzania (TB-CAPT CORE)

2024 · Celso Khosa, Marta Cossa, et al. · SSRN Electronic Journal

PA-310 User perspectives on Molbio MTB for use as a decentralized point-of-care diagnostic test in Mozambique and Tanzania

2023 · Maria Del Mar Castro Noriega, Marta Cossa, et al. · BMJ Global Health

Scaling up shorter TB preventive treatment is long overdue

2022 · D. Nguenha, M. Cossa, et al. · The International Journal of Tuberculosis and Lung Disease

Works count: 16

Citation count: 108

H-index: 6

I10-index: 5